🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Diffuse Glioma

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow NCT06492486Phase 21 site📍 Mumbai Tata Memorial Centre · Tests: Adaptive radiotherapy Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma NCT01106794n/a1 site📍 Washington D.C. Children's National Research Institute Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas NCT07468136Phase 1, Phase 21 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab Atovaquone Combined With Radiation in Children With Malignant Brain Tumors NCT06624371Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Atovaquone, Radiation Therapy CAR T Cells to Target GD2 for DMG NCT05544526Phase 11 site📍 London University College, London · Tests: GD2 CAR T cells Combination Therapy for the Treatment of Diffuse Midline Gliomas NCT05009992Phase 232 sites📍 Birmingham📍 Los Angeles📍 San Diego University of California, San Francisco · Tests: ONC201, Radiation Therapy, Paxalisib, DNX-2401 ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors NCT04732065Phase 17 sites📍 San Francisco📍 Washington D.C.📍 Atlanta Sabine Mueller, MD, PhD · Tests: ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) MCT for the Harvard/UCSF ROBIN Center NCT06000787NA2 sites📍 San Francisco📍 Boston Brigham and Women's Hospital · Tests: External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG) Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors NCT07664176Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma NCT05717153EARLY Phase 11 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Computed Tomography, Eflornithine, Magnetic Resonance Imaging, Polyamine Transport Inhibitor AM… Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification NCT05259605n/a42 sites📍 Innsbruck📍 Vienna📍 Aalst European Organisation for Research and Treatment of Cancer … · Tests: Observational Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT) NCT07796061Phase 11 site📍 Washington D.C. Children's National Research Institute · Tests: TAA-T Cell, BBB Disruption xPedite: A Study to Expedite DIPG and DMG Research NCT06140719n/a1 site📍 Los Altos xCures Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors NCT04185038Phase 11 site📍 Seattle Seattle Children's Hospital · Tests: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults NCT06305910Phase 11 site📍 Minneapolis OX2 Therapeutics · Tests: Treatment with CD200AR-L ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) NCT05580562Phase 3162 sites📍 Phoenix📍 Phoenix📍 Phoenix Jazz Pharmaceuticals · Tests: Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) NCT04099797Phase 11 site📍 Houston Baylor College of Medicine · Tests: C7R-GD2.CART cells (IV and ICV infusion), C7R-GD2.CART cells (IV and ICV infusion) Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: NCT07608003n/a1 site📍 Changsha Xiangya Hospital of Central South University 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours NCT06630260Phase 1, Phase 23 sites📍 Cambridge📍 Sutton📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Avutometinib, Defactinib, Temozolomide STRatifying Adult DIffuse Lower-grade Gliomas Based on Their VARIed Metabolic Profiles (STRADIVARI Project) NCT06794736n/a4 sites📍 Bari📍 Bari📍 Milan I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma NCT05717699Phase 11 site📍 Beijing Capital Medical University · Tests: Ad-TD-nsIL12 A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma NCT04250064Phase 21 site📍 Mumbai Tata Memorial Centre · Tests: Bevacizumab Injection, Ultra-low-dose RT Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG NCT06221553Phase 11 site📍 Bangkok Chulalongkorn University · Tests: B7H3 specific CAR T cell with IL-7Ra signaling domain Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 NCT05476939Phase 356 sites📍 Brussels📍 Leuven📍 Aarhus Gustave Roussy, Cancer Campus, Grand Paris · Tests: Everolimus, ONC201, Radiotherapy Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma NCT06468176NA8 sites📍 Montpellier📍 Amiens📍 Bordeaux Institut du Cancer de Montpellier - Val d'Aurelle · Tests: Cognitive Behavioral Therapy (CBT) neuropsychologist SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma NCT04923126Phase 1, Phase 21 site📍 Memphis St. Jude Children's Research Hospital · Tests: Mirdametinib Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253Phase 220 sites📍 Aurora📍 Washington D.C.📍 Chicago Nationwide Children's Hospital · Tests: Ribociclib, Everolimus, Temozolomide (TMZ) Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors NCT06914479Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration 18F-Fluciclovine PET-MRI in High-grade Glioma NCT05553041EARLY Phase 11 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: 18F-Fluciclovine PET-MRI
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy